Pharma BD Deal Intelligence
Deal positioned as Otsuka's largest US acquisition, anchoring its post-Abilify CNS strategy alongside Rexulti and Samsca.
Avanir shares jumped on a 13.3% premium offer; analysts noted Nuedexta's $74.2M nine-month sales (+47% YoY) and AVP-786's late-stage potential as the value…
EP Vantage cautioned the steep valuation rests on AVP-786 succeeding in Alzheimer's agitation — a regulatory pathway 'no easier than the currently approved…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Otsuka agreed to acquire Avanir Pharmaceuticals for $17.00 per share, valuing the company at approximately $3.5B. Deal added Nuedexta for pseudobulbar affect and the late-stage AVP-786 program for Alzheimer's agitation, completing Otsuka's transformation toward a global CNS pharma. Closed Q1 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. / Avanir Pharmaceuticals, Inc. (this deal) | 2014 | $3.5B | 41 |
| Otsuka Pharmaceutical Co., Ltd. / Transcend Therapeutics, Inc. | 2026 | $1.2B | — |
| Otsuka Pharmaceutical Co., Ltd. / 4D Molecular Therapeutics, Inc. | 2025 | $421M | — |
| Otsuka Pharmaceutical Co., Ltd. / Cantargia AB | 2025 | $613M | — |
| Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc. | 2024 | $1.1B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2014 deals · Otsuka Pharmaceutical Co., Ltd. deals · Neurology deals